

# Pedro M Folegatti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/157846/publications.pdf>

Version: 2024-02-01

34  
papers

11,560  
citations

331259

21  
h-index

395343

33  
g-index

42  
all docs

42  
docs citations

42  
times ranked

17534  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. <i>Lancet Microbe</i> , The, 2022, 3, e11-e20.	3.4	25
2	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	2.3	6
3	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0228321.	1.8	5
4	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
5	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
6	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
7	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	6.3	3,887
8	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
9	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
10	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet</i> , The, 2021, 397, 881-891.	6.3	979
11	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	2.1	3
12	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1351-1362.	6.3	540
13	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	2.2	73
14	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	5.8	31
15	Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). <i>Vaccines</i> , 2021, 9, 851.	2.1	6
16	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.	2.1	190
17	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
18	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900

#	ARTICLE	IF	CITATIONS
19	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
20	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
21	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
22	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
23	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	4.6	182
24	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019, 7, 40.	2.1	19
25	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33.	2.1	23
26	A phase IIb study to determine the safety and efficacy of candidate Influenza Vaccine MVA-NP+M1 in combination with licensed Inactivated influenza vaccine in adults aged 65 years and above (INVICTUS): a study protocol. <i>F1000Research</i> , 2019, 8, 719.	0.8	14
27	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. <i>EBioMedicine</i> , 2018, 29, 146-154.	2.7	100
28	Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.	1.7	43
29	Para-kala-azar dermal leishmaniasis in a patient in Brazil: a case report. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2018, 51, 105-107.	0.4	2
30	A systematic review on malaria sero-epidemiology studies in the Brazilian Amazon: insights into immunological markers for exposure and protection. <i>Malaria Journal</i> , 2017, 16, 107.	0.8	24
31	Efficacy of ChAdOx1 nCoV-19&nbsp;(AZD1222)&nbsp;Vaccine Against SARS-CoV-2 VOC&nbsp;202012/01&nbsp;(B.1.1.7). <i>SSRN Electronic Journal</i> , 0, , .	0.4	36
32	Single Dose&nbsp;Administration,&nbsp;And&nbsp;The&nbsp;Influence Of&nbsp;The&nbsp;Timing Of&nbsp;The&nbsp;Booster Dose&nbsp;On Immunogenicity and Efficacy Of&nbsp;ChAdOx1 nCoV-19&nbsp;(AZD1222)&nbsp;Vaccine. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
33	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
34	Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). <i>SSRN Electronic Journal</i> , 0, , .	0.4	23